These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31406224)

  • 1. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma.
    Nampoothiri RV; Kasudhan KS; Patil AN; Malhotra P; Khadwal A; Prakash G; Jain A; Malhotra S; Verma Attri S; Varma N; Varma S; Lad DP
    Bone Marrow Transplant; 2019 Dec; 54(12):2088-2095. PubMed ID: 31406224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Pai AA; Devasia AJ; Panetta JC; Mani S; Stallon Illangeswaran RS; Mohanan E; Balakrishnan B; Lakshmi KM; Kulkarni U; Aboobacker FN; Korula A; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):130-135.e1. PubMed ID: 31791694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
    Bashir Q; Shah N; Parmar S; Wei W; Rondon G; Weber DM; Wang M; Orlowski RZ; Thomas SK; Shah J; Qureshi SR; Dinh YT; Popat U; Anderlini P; Hosing C; Giralt S; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2012 Jan; 53(1):118-22. PubMed ID: 21780997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma.
    Lad DP; Malhotra P; Patil AN; Nampoothiri RV; Kasudhan KS; Khadwal A; Prakash G; Jain A; Malhotra S; Varma N; Attri SV; Varma S
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):114-118. PubMed ID: 32622756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
    Costa LJ; Landau HJ; Chhabra S; Hari P; Innis-Shelton R; Godby KN; Hamadani M; Tamari R; Anderton K; Dixon P; Giralt SA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1379-1385. PubMed ID: 29410301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
    Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
    Bashir Q; Thall PF; Milton DR; Fox PS; Kawedia JD; Kebriaei P; Shah N; Patel K; Andersson BS; Nieto YL; Valdez BC; Parmar S; Rondon G; Delgado R; Hosing C; Popat UR; Oran B; Ciurea SO; Lin P; Weber DM; Thomas SK; Lee HC; Manasanch EE; Orlowski RZ; Williams LA; Champlin RE; Qazilbash MH
    Lancet Haematol; 2019 May; 6(5):e266-e275. PubMed ID: 30910541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.
    Gul Z; Bashir Q; Cremer M; Yusuf SW; Gunaydin H; Arora S; Slone S; Nieto Y; Sherwani N; Parmar S; Shah N; Dinh YT; Hosing CM; Popat UR; Kebriaei P; Shpall EJ; Giralt SA; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2015 Feb; 56(2):533-5. PubMed ID: 24882259
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
    Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e59-63. PubMed ID: 24378319
    [No Abstract]   [Full Text] [Related]  

  • 11. Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
    Saini NY; Patel R; Varma A; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
    Am J Hematol; 2019 Jan; 94(1):E2-E5. PubMed ID: 30300461
    [No Abstract]   [Full Text] [Related]  

  • 12. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
    Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem bone marrow transplantation in multiple myeloma.
    Chng WJ
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074003
    [No Abstract]   [Full Text] [Related]  

  • 15. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melphalan 140 mg/m
    Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
    Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
    Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL;
    Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature].
    Abdelkefi A; Ladeb S; Ben Othman T; Torjman L; Jeddi R; Ben Abdeladhim A
    Tunis Med; 2000 Oct; 78(10):548-56. PubMed ID: 11190737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.